Login Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

  • Watchlist

    Keep track of companies that you follow and research.

  • 10 Years of Data

    Full access to our data with predictions and indicators that we calculate daily.

  • Screener

    Full access to our screener with tons of custom values and customizable email notifications.

  • XLS Exports

    Excel export of financials and screeners you define and save.

Subscribe now
Screener Weekly Summary

Atara Biotherapeutics, Inc. ATRA

Healthcare  —  Biotechnology
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Atara Biotherapeutics, Inc. (ATRA) Business Profile

Company Overview

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is a leading biotechnology company focused on developing transformative therapies for patients with serious diseases, particularly in the field of immunotherapy. Founded in 2012, the company is headquartered in South San Francisco, California. Atara was established with the mission of leveraging cutting-edge science to create innovative treatments that address unmet medical needs. The company’s name is derived from the Hebrew word for “crown,” symbolizing its commitment to excellence and leadership in the biopharmaceutical industry.

Atara’s leadership team is composed of seasoned professionals with extensive experience in biotechnology, pharmaceuticals, and healthcare. The company’s CEO, Pascal Touchon, has been instrumental in driving Atara’s strategic vision and operational growth. Under his leadership, Atara has made significant advancements in its pipeline and partnerships. Other key executives include Dr. Jakob Dupont, Chief Medical Officer, and Joe Newell, Chief Operations Officer, who bring decades of expertise in clinical development and operational excellence.

Core Business Segments

Atara Biotherapeutics operates primarily in the field of immunotherapy, with a focus on allogeneic T-cell therapies. The company’s core business segments include:

1. Allogeneic T-Cell Immunotherapy

Atara is a pioneer in developing allogeneic (off-the-shelf) T-cell therapies, which are designed to be readily available for patients without the need for personalized manufacturing. This approach significantly reduces treatment timelines and costs. Key products in this segment include:

  • Tab-cel® (tabelecleucel): Atara’s lead product candidate, Tab-cel®, is an allogeneic T-cell therapy being developed for the treatment of Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD). It is currently in late-stage clinical trials and has shown promising results in addressing this rare and life-threatening condition.
  • ATA188: This investigational therapy targets progressive forms of multiple sclerosis (MS) by addressing EBV-infected B cells and plasma cells, which are believed to play a role in the disease’s progression.

2. Oncology

Atara is also exploring the potential of its T-cell platform in oncology. The company is developing therapies aimed at treating various cancers, leveraging its expertise in immunotherapy to create innovative solutions for patients.

3. Neurology

In addition to oncology, Atara is expanding its focus to include neurological disorders. ATA188, mentioned earlier, is a key product in this segment, with the potential to transform the treatment landscape for progressive MS.

Business Model

Atara Biotherapeutics operates on a business model that integrates cutting-edge science, strategic partnerships, and a focus on patient-centric solutions. The company generates revenue through:

  • Collaborations and Licensing Agreements: Atara has established partnerships with leading pharmaceutical companies to co-develop and commercialize its therapies. For example, the company has a collaboration with Bayer to develop ATA2271 and ATA3271, which are CAR T-cell therapies for solid tumors.
  • Clinical Development and Commercialization: Atara invests heavily in clinical trials to bring its therapies to market. Once approved, the company plans to commercialize its products either independently or through partnerships.
  • Manufacturing Capabilities: Atara has built a state-of-the-art manufacturing facility in Thousand Oaks, California, to support the production of its allogeneic T-cell therapies. This facility enables the company to maintain control over the quality and scalability of its products.

Strategic Direction

Atara Biotherapeutics is committed to advancing its pipeline of innovative therapies and expanding its presence in the global biopharmaceutical market. Key strategic priorities include:

  • Regulatory Approvals: The company is focused on securing regulatory approvals for Tab-cel® in the United States and Europe. These approvals will mark a significant milestone in Atara’s journey and pave the way for future growth.
  • Pipeline Expansion: Atara is actively exploring new indications and therapeutic areas for its T-cell platform. The company aims to expand its pipeline to address a broader range of diseases, including additional cancers and autoimmune disorders.
  • Global Partnerships: Atara continues to seek strategic partnerships to accelerate the development and commercialization of its therapies. These collaborations enable the company to leverage external expertise and resources while focusing on its core competencies.
  • Sustainability Goals: Atara is committed to sustainability and ethical practices in its operations. The company aims to minimize its environmental footprint and promote diversity and inclusion within its workforce.

Competitive Landscape

Atara Biotherapeutics operates in a highly competitive and rapidly evolving industry. Key competitors include:

  • Adaptimmune Therapeutics: A leader in T-cell therapy, Adaptimmune focuses on developing SPEAR T-cells for cancer treatment.
  • Bluebird Bio: Known for its gene and cell therapies, Bluebird Bio is a major player in the field of immunotherapy.
  • Kite Pharma (a Gilead Company): Kite Pharma specializes in CAR T-cell therapies for cancer and is a direct competitor in the immunotherapy space.
  • Allogene Therapeutics: Another pioneer in allogeneic T-cell therapies, Allogene Therapeutics competes with Atara in developing off-the-shelf solutions.

Risk Factors

Atara Biotherapeutics faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The approval process for biopharmaceutical products is complex and time-consuming. Delays or rejections by regulatory authorities could hinder Atara’s growth.
  • Market Dependence: Atara’s success is heavily reliant on the commercial success of its lead product candidates, particularly Tab-cel®.
  • Supply Chain Disruptions: The company’s manufacturing operations could be affected by supply chain disruptions, impacting the availability of raw materials and production timelines.
  • Competition: The biopharmaceutical industry is highly competitive, with numerous companies vying for market share. Atara must continuously innovate to stay ahead of its competitors.
  • Financial Risks: As a clinical-stage company, Atara incurs significant R&D expenses and may require additional funding to sustain its operations.

Recent Developments

Atara has made significant progress in recent months, including:

  • Regulatory Submissions: The company has submitted a Biologics License Application (BLA) for Tab-cel® to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA).
  • Clinical Trial Updates: Atara has reported positive interim results from its Phase 2 clinical trial of ATA188 for progressive MS, demonstrating its potential to improve patient outcomes.
  • Partnerships: The company has expanded its collaboration with Bayer to include additional CAR T-cell programs, strengthening its position in the oncology market.
  • Manufacturing Milestones: Atara’s manufacturing facility has achieved key operational milestones, ensuring the scalability and quality of its therapies.

Investment Considerations

Investors considering Atara Biotherapeutics should weigh the following factors:

Strengths

  • Innovative Pipeline: Atara’s focus on allogeneic T-cell therapies positions it as a leader in the immunotherapy space.
  • Strong Partnerships: Collaborations with industry leaders like Bayer enhance the company’s capabilities and market reach.
  • Experienced Leadership: Atara’s management team brings extensive expertise in biotechnology and healthcare.

Risks

  • Regulatory Uncertainty: The approval process for biopharmaceutical products is inherently risky and unpredictable.
  • Financial Dependence: As a clinical-stage company, Atara relies on external funding to sustain its operations.
  • Market Competition: The company faces intense competition from established players and emerging startups.

Conclusion

Atara Biotherapeutics is at the forefront of innovation in the biopharmaceutical industry, with a strong focus on allogeneic T-cell therapies. The company’s pioneering approach, robust pipeline, and strategic partnerships position it for long-term success. While challenges remain, including regulatory and financial risks, Atara’s commitment to addressing unmet medical needs and advancing patient care underscores its potential for growth and market leadership.